Abstract

This study involves the efficacy of pregabalin combined with celecoxib for acute pain treatment in patients with lumbar disc herniation. Selected 142 patients with acute pain due to lumbar disc herniation undertreated in our hospital from May 2019 to March 2021 and randomly divided them into a control group and a study group. Control group (n=71) accepted conventional treatment with celecoxib, after study group (n=71) accepted the same treatment as control group, they received another pregabalin, patients in both groups were treated continuously for 2 w. Visual analog scale scores of pain of both groups in 2, 7 and 14 d treatment were lower than those before treatment (p<0.05). Both groups had lower Oswestry disability index scores on the 7 and 14 d of treatment than before treatment (p<0.05) and Oswestry disability index scores of 14 d treatment were lower than those of 7 d treatment (p<0.05), but study group had lower Oswestry disability index scores in 7 and 14 d treatment than control group (p<0.05). Serum tumor necrosis factor alpha and interleukin-6 levels decreased after treatment in both groups (p<0.05), but study group possessed lower serum tumor necrosis factor alpha and interleukin-6 levels than control group (p<0.05). Both groups had no significant difference in adverse effects rate during the treatment period (p>0.05). Pregabalin combined with celecoxib can effectively relieve pain in patients with acute pain due to lumbar disc herniation, improve lumbar spine function, attenuate levels of inflammatory factors and has a good safety profile.